Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    9647875 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell Lymphoma
Interventions: Drug: rituximab;   Drug: doxorubicin;   Drug: cyclophosphamide

Indicates status has not been verified in more than two years